Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Hammond, LA
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Hammond, LA
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Chevy Chase, MD
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Rochester, MN
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Mexico, MO
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Mexico, MO
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Great Neck, NY
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Charlotte, NC
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Nashville, TN
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
San Antonio, TX
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Ogden, UT
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated:  12/14/2015
Research Site
mi
from
Kurralta Park,
Safety Study in Subjects With Crohn's Disease
A Long-term Assessment of Safety and Efficacy of AMG 827 Treatment in Subjects With Crohn's Disease
Status: Enrolling
Updated: 12/14/2015
Research Site
mi
from
Kurralta Park,
Click here to add this to my saved trials
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
Status: Enrolling
Updated:  12/16/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
Status: Enrolling
Updated: 12/16/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Antibiotic Resistant Community-Acquired E. Coli
Antibiotic Resistant Community-Acquired E. Coli
Status: Enrolling
Updated:  12/16/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Antibiotic Resistant Community-Acquired E. Coli
Antibiotic Resistant Community-Acquired E. Coli
Status: Enrolling
Updated: 12/16/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation
Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation
Status: Enrolling
Updated:  12/16/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation
Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation
Status: Enrolling
Updated: 12/16/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Lexington, KY
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Baltimore, MD
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Omaha, NE
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Hackensack, NJ
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Buffalo, NY
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
Houston, TX
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated:  12/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Study of MLN8237 in Patients With Advanced Hematological Malignancies
An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients With Advanced Hematological Malignancies
Status: Enrolling
Updated: 12/17/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety and Efficacy of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Status: Enrolling
Updated:  12/17/2015
OPKO Renal
mi
from
Bannockburn, IL
Safety and Efficacy of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Status: Enrolling
Updated: 12/17/2015
OPKO Renal
mi
from
Bannockburn, IL
Click here to add this to my saved trials
Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass
Status: Enrolling
Updated:  12/21/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels
Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass
Status: Enrolling
Updated: 12/21/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Birmingham, AL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Montgomery, AL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Montgomery, AL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Lakewood, CA
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Lakewood, CA
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Monterey, CA
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Monterey, CA
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Orange, CA
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
San Carlos, CA
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
San Carlos, CA
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
San Diego, CA
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Lafayette, CO
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Lafayette, CO
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Littleton, CO
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Littleton, CO
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Lone Tree, CO
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Lone Tree, CO
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Bridgeport, CT
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Hamden, CT
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Hamden, CT
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Hartford, CT
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
New Haven, CT
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Stratford, CT
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Stratford, CT
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Hollywood, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Jacksonville, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Largo, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Largo, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Lauderdale Lakes, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Naples, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Naples, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Ormond Beach, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated:  12/21/2015
Clinical Research Facility
mi
from
Winter Park, FL
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
Status: Enrolling
Updated: 12/21/2015
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials